[A19-10] Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis

Last updated 05.12.2022

Project no.:
A19-10

Commission:
Commission awarded on 30.01.2019 by the Federal Joint Committee (G-BA).

Report type:
Report

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

05.12.2022

IQWiG's final report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab now available in Englis...

Press release

Extract of the final report: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis

EN, PDF, 719 kB, PDF

published on Jun 28, 2023
Final report: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis

DE, PDF, 3 MB, PDF

published on Dec 5, 2022
Documentation of comments on the preliminary report: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis

DE, PDF, 3 MB, PDF

published on Dec 5, 2022
Preliminary report: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis

DE, PDF, 3 MB, PDF

published on Jun 2, 2022
Documentation of comments on the report plan: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis

DE, PDF, 4 MB, PDF

published on Jun 2, 2022
Report plan: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis

DE, PDF, 248 kB, PDF

published on Dec 10, 2019

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.